TRIUMPH-3: Retatrutide Phase 3 trial (NCT05882045)
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 1,946
- actual
- Start
- 30 May 2023 (actual)
- Primary completion
- 16 Apr 2026 (actual)
- Sponsor
- Eli Lilly and Company
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Retatrutide Dose 1 | Experimental | Drug: Retatrutide | Participants will receive retatrutide subcutaneously (SC). |
| Retatrutide Dose 2 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 80 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 80 |
| Change from Baseline in Waist Circumference | Baseline, Week 80 |
| Percent Change from Baseline in Total Cholesterol | Baseline, Week 80 |
| Percent Change from Baseline in Triglycerides | Baseline, Week 80 |
| Change from Baseline in Systolic Blood Pressure (SBP) | Baseline, Week 80 |
| Change from Baseline in Diastolic Blood Pressure (DBP) | Baseline, Week 80 |
| Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline, Week 80 |
| Percent Change from Baseline in Fasting Insulin | Baseline, Week 80 |
| Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score | Baseline, Week 80 |
| Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC) | Baseline to Week 80 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.